logo

Atara Biotherapeutics, Inc. (ATRA)



Trade ATRA now with
  Date
  Headline
5/17/2018 9:12:17 AM Atara To Present Long-Term Tab-cel Phase 2 Outcomes For Patients With Epstein-Barr
5/8/2018 7:13:13 AM Atara Expands T-Cell Immunotherapy Collaboration To Advance Next-Generation CAR T Technologies
5/8/2018 7:09:34 AM Atara Biotherapeutics Q1 Loss Per Share $1.05 Vs Loss $0.88 Last Year
5/1/2018 8:05:58 AM Atara Biotherapeutics Appoints Manuela Maronati As General Manager, Europe
4/9/2018 4:48:09 PM Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/2/2018 8:33:33 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
3/20/2018 7:41:16 AM William Blair Reiterates Atara Biotherapeutics, Inc. (ATRA) At Outperform
2/28/2018 9:44:31 PM Atara Biotherapeutics Announces Pricing Of Underwritten Public Offering Of 4.29 Mln Shares At $35.00/shr
2/27/2018 7:16:34 AM Atara Biotherapeutics Posts Q4 Net Loss Of $35.3 Mln Or 41.15/share
1/19/2018 11:31:13 AM Wedbush Is Increasing Atara Biotherapeutics, Inc. (ATRA) FY18 Estimate To -3.30 From -4.17
1/19/2018 11:15:02 AM Atara Biotherapeutics Stock Price Target Raised To $70 From $47 At Canaccord
1/10/2018 8:05:57 AM Atara Receives FDA Clearance Of IND Application To Proceed With Patient Enrollment For Phase 1 Clinical Study On ATA188
1/3/2018 11:03:22 PM Atara Biotherapeutics Announces Pricing Of Public Offering Of 7 Mln Common Stock At $18.25/Shr
1/2/2018 8:18:18 AM Atara Initiates Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory EBV+PTLD
12/29/2017 6:02:23 AM Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel
12/11/2017 10:07:56 AM Atara Announces Updated Positive Interim Results From Multicenter Expanded Access Study Of Tabelecleucel